Compare · ORKA vs OXFD
ORKA vs OXFD
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Oxford Immunotec Global PLC (OXFD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and OXFD operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA carries a market cap of $6.74B.
- ORKA has hit the wire 11 times in the past 4 weeks while OXFD has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for OXFD).
- Company
- Oruka Therapeutics Inc.
- Oxford Immunotec Global PLC
- Price
- -
- -
- Market cap
- $6.74B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- News (4w)
- 11
- 0
- Recent ratings
- 11
- 0
Latest ORKA
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
- General Counsel Quinlan Paul T exercised 52,000 shares at a strike of $11.60 and sold $5,641,409 worth of shares (52,000 units at $108.49) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,066,572 worth of shares (10,000 units at $106.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Latest OXFD
- SEC Form SC 13G filed by Oxford Immunotec Global PLC
- SEC Form 15-12B filed by Oxford Immunotec Global PLC
- SEC Form S-8 POS filed
- SEC Form 4: Herm Rosenman disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: E T Matthew Mclaughlin disposed to the issuer $1,350,954 worth of Ordinary Shares (61,407 units at $22.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: A Richard Sandberg disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: R. Mark Klausner disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Patricia Randall disposed to the issuer $611,710 worth of Ordinary Shares (27,805 units at $22.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Louise Janet Kidd disposed to the issuer $246,554 worth of Ordinary Shares (11,207 units at $22.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: J Patrick Balthrop disposed to the issuer $177,782 worth of Ordinary Shares (8,081 units at $22.00), decreasing direct ownership by 100% to 0 units